

Date: February 12, 2025

Ref. No.: KDL/SE/126/2024-25

To, BSE Limited Corporate Relationship Department 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 Scrip Code: 543328	To, National Stock Exchange of India Limited Exchange Plaza, Plot No. C-1, Block G, Bandra Kurla Complex, Bandra (East) Mumbai – 400051 NSE Symbol: KRSNAA
--	--

Subject: Outcome of Board Meeting held on February 12, 2025.

In compliance with Regulation 30 read with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we would like to inform you that the Board of Directors of the Company at its meeting held today i.e. February 12, 2025, inter-alia approved and/or took note of the following items:

- Unaudited (Standalone and Consolidated) Financial Results for the quarter and nine months ended December 31, 2024;
- Cessation of Mr. Yash Mutha from the designation of Manager.
- Appointment of Mr. Yash Mutha (DIN 07285523) as Managing Director of the Company.
- Updated Policy on Code of Practices and Procedures for Fair disclosure of Unpublished Price Sensitive Information formulated in terms of Regulation 8 of SEBI (Prohibition of Insider Trading) Regulations, 2015.
- List of the Key Managerial Personnel's (KMP) for the purpose of determining the materiality of an event or information.

Accordingly, kindly find enclosed the following:

- Limited Review Report and Unaudited (Standalone and Consolidated) Financial Results for the quarter and nine months ended December 31, 2024.

The Board Meeting commenced at 09:30 Hrs. (IST) and concluded at 15:10 Hrs. (IST).

The aforesaid results are also being disseminated on the Company's Website. This is for your information and records.

For **Krsnaa Diagnostics Limited**



Sujoy Sudipta Bose
Company Secretary & Compliance Officer
Encl: as above

Independent Auditor's Review Report on Standalone unaudited financial results of Krsnaa Diagnostics Limited for the quarter and year to date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of Krsnaa Diagnostics Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of Krsnaa Diagnostics Limited (hereinafter referred to as 'the Company') for the quarter ended December 31, 2024 and the year to-date results for the period from April 01, 2024 to December, 31, 2024 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We draw attention to Note No. 5 of the unaudited financial results in respect of additions made by the Income Tax Authorities, consequent to an assessment order passed and a demand raised on the Company for the assessment year ("AY") 2022-23 in relation to search assessment proceedings conducted under section 132(1) and section 133A of the Income Tax Act, 1961. The Company has filed an appeal with the Joint Commissioner (Appeals) or Commissioner of Income- Tax (Appeals) against the said order, and has paid tax under protest of Rs. 39.26 million during the nine months ended December 31, 2024. Further as explained in the note, the management believes that considering the on-going




MSKA & Associates

Chartered Accountants

assessment proceedings and the appeal filed by the Company, the impact on the previous period financial statements and on the current period financial results for the quarter and nine months ended December 31, 2024, including income tax, interest and other charges if any, will not have material impact.

Our conclusion is not modified in respect of the above matter.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W



Vikram Dhanania
Partner
Membership No.: 060568
UDIN: 25060568BMJJPP7399



Place: Bengaluru
Date: February 12, 2025

1. Statement of Unaudited Standalone Financial Results for the quarter and nine months ended December 31, 2024

(INR Million, except earnings per share)

Sr. No.	Particulars	Quarter ended			Nine months ended		Year ended
		December 31, 2024	September 30, 2024	December 31, 2023	December 31, 2024	December 31, 2023	March 31, 2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
	Revenue from operations	1,651.57	1,787.22	1,515.52	5,070.42	4,306.88	5,900.19
	Other income	92.90	46.04	40.78	212.12	124.58	167.96
	Total Income	1,744.47	1,833.26	1,556.30	5,282.54	4,431.46	6,068.15
2	Expenses						
	Cost of material consumed	399.02	449.13	343.61	1,277.16	980.47	1,410.40
	Employee benefits expense	289.87	281.12	261.19	858.64	685.38	975.69
	Finance costs	61.28	63.87	41.39	178.18	91.51	164.66
	Depreciation and amortization expense	226.89	222.01	212.31	663.56	564.30	745.47
	Fees to hospitals and others	126.70	170.67	178.98	420.78	518.44	609.34
	Other expenses	357.05	361.50	350.15	1,080.31	1,093.71	1,443.14
	Total Expenses	1,460.81	1,548.30	1,387.63	4,478.63	3,933.81	5,348.70
3	Profit before tax (1) - (2)	283.66	284.96	168.67	803.91	497.65	719.45
4	Tax expenses						
	Income Tax charge	37.81	51.03	27.60	128.80	82.75	114.42
	Income Tax charge relating to earlier period	0.50	-	(0.15)	0.50	(6.41)	(6.41)
	Deferred tax charge/(credit)	29.35	14.28	5.37	57.15	19.87	25.83
	Total tax expenses	67.66	65.31	32.82	186.45	96.21	133.84
5	Profit for the period/year (3) - (4)	216.00	219.65	135.85	617.46	401.44	585.61
6	Other comprehensive income						
	Items that will not be reclassified subsequently to profit and loss:						
	Re-measurement gains on defined benefit plans	(1.33)	(0.65)	3.62	(2.68)	7.94	(2.44)
	Income tax effect	0.33	0.16	(0.91)	0.67	(1.99)	0.61
	Total other comprehensive income for the period/year	(1.00)	(0.49)	2.71	(2.01)	5.95	(1.83)
7	Total comprehensive income for the period/year, net of tax (5+6)	215.00	219.16	138.56	615.45	407.39	583.78
8	Paid-up equity share capital (Face Value of Rs. 5/- each)	161.45	161.45	161.45	161.45	161.45	161.45
	Other equity						7,990.96
	Earnings per share (Not annualised for quarter & nine months):						
	Basic (Rs.)	6.69	6.80	4.28	19.12	12.74	18.45
	Diluted (Rs.)	6.54	6.64	4.16	18.72	12.33	17.83



For and on behalf of Board of Directors
Krsnaa Diagnostics Limited

Rajendra Mutha

Rajendra Mutha
Chairman & Whole-time Director
DIN: 01066737

Krsnaa Diagnostics Limited

CIN:L74900PN2010PLC138068

Notes to Unaudited Standalone Financial Results:

2. These standalone unaudited financial results have been reviewed by the Audit Committee on February 11, 2025 and approved by the Board of Directors at its meeting held on February 12, 2025.

3. The above Statement has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015, as amended.

4. The Company's operations predominantly relate to providing diagnostic services in radiology and pathology services. The Chief Operating Decision Maker (CODM) reviews the operations of the Company as one operating segment. Hence, no separate segment information has been furnished herewith.

5. Pursuant to search and seizure proceedings initiated under the provisions of section 132(1) and section 133A of the Income Tax Act, 1961 on the Company on July 20, 2022, an assessment order dated March 31, 2024 u/s 143(3) of the Income Tax Act, 1961 ("the Order"), has been received by the Company for the assessment year ("AY") 2022-23. The Income tax authorities have allegedly made additions on account of undisclosed income and disallowance of certain deductions claimed by the Company in the tax returns filed in respect of AY 2022-23 and raised a demand of Rs.196.3 million.

The Company has provided the requisite disclosure to the stock exchange on July 29, 2022, with respect to the search operations, and on April 1, 2024, with respect to the receipt of the Order in accordance with Regulation 30 of the SEBI (LODR) Regulations, 2015 (as amended). The Company has filed an appeal with the Joint Commissioner (Appeals) or Commissioner of Income-Tax (Appeals) against the Order on April 29, 2024, and have paid tax under protest on August 6, 2024, amounting to Rs. 39.26 million.

The management of the Company, based on available information, underlying evidence and opinion from tax consultants and experts, is of the view that the said demand is not tenable and will not have any material impact on the Company's financial position as of December 31, 2024, and on its performance for the quarter and nine months ended on that date.

6. Previous period/year figures have been regrouped/ rearranged wherever considered necessary.



For and on behalf of Board of Directors
Krsnaa Diagnostics Limited

Rajendra Mutha
Chairman & Whole-time Director
DIN: 01066737

Place: Pune

Date: February 12, 2025

Independent Auditor's Review Report on Consolidated unaudited financial results of Krsnaa Diagnostics Limited for the quarter and year to date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Krsnaa Diagnostics Limited

1. We have reviewed the accompanying Statement of consolidated unaudited financial results of Krsnaa Diagnostics Limited (hereinafter referred to as 'the Holding Company') and its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended December 31, 2024 and the year to-date results for the period from April 01, 2024 to December 31, 2024 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Krsnaa Diagnostics (Mohali) Private Limited	Wholly Owned Subsidiary
2	KDPL Diagnostics (Amritsar) Private Limited	Wholly Owned Subsidiary
3	KDPL Diagnostics (Bathinda) Private Limited	Wholly Owned Subsidiary
4	KDPL Diagnostics (Jalandhar) Private Limited	Wholly Owned Subsidiary
5	KDPL Diagnostics (Ludhiana) Private Limited	Wholly Owned Subsidiary
6	KDPL Diagnostics (Patiala) Private Limited	Wholly Owned Subsidiary
7	KDPL Diagnostics (Sas Nagar) Private Limited	Wholly Owned Subsidiary
8	Krsnaa Retail Private Limited	Wholly Owned Subsidiary



MSKA & Associates

Chartered Accountants


5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditor referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We draw attention to Note No. 5 of the unaudited financial results in respect of additions made by the Income Tax Authorities, consequent to an assessment order passed and a demand raised on the Holding Company for the assessment year ("AY") 2022-23 in relation to search assessment proceedings conducted under section 132(1) and section 133A of the Income Tax Act, 1961. The Holding Company has filed an appeal with the Joint Commissioner (Appeals) or Commissioner of Income- Tax (Appeals) against the said order, and has paid tax under protest of Rs. 39.26 million during the nine months ended December 31, 2024. Further as explained in the note, the management believes that considering the on-going assessment proceedings and the appeal filed by the Holding Company, the impact on the previous period financial statements and on the current period financial results for the quarter and nine months ended December 31, 2024, including income tax, interest and other charges if any, will not have material impact.

Our conclusion is not modified in respect of above matter.

7. We did not review the interim financial information of one subsidiary included in the Statement, whose interim financial information reflect total revenues of Rs. 38.58 million and Rs. 49.84 million, total net loss after tax of Rs. 17.59 million and Rs. 42.04 million and total comprehensive loss of Rs. 17.59 million and Rs. 42.04 million for the quarter ended December 31, 2024 and for the period from April 01, 2024 to December 31, 2024, respectively, as considered in the Statement. This interim financial information has been reviewed by other auditor whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of the above matter with respect to our reliance on the work done by and report of the other auditor.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W


Vikram Dhanania
Partner
Membership No.: 060568
UDIN: 25060568BMJJPQ7923



Place: Bengaluru
Date: February 12, 2025

1. Statement of Unaudited Consolidated Financial Results for the quarter and nine months ended December 31, 2024

(INR Million, except earnings per share)

Sr. No.	Particulars	Quarter ended			Nine months ended		Year ended
		December 31, 2024	September 30, 2024	December 31, 2023	December 31, 2024	December 31, 2023	March 31, 2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
	Revenue from operations	1,745.12	1,863.40	1,583.22	5,310.84	4,533.50	6,196.33
	Other income	92.37	45.94	40.78	211.47	124.58	167.96
	Total Income	1,837.49	1,909.34	1,624.00	5,522.31	4,658.08	6,364.29
2	Expenses						
	Cost of material consumed	399.02	449.13	343.61	1,277.16	980.47	1,410.40
	Employee benefits expense	358.63	350.55	296.52	1,039.96	790.10	1,114.65
	Finance costs	61.33	63.89	41.45	178.38	91.69	164.88
	Depreciation and amortization expense	227.02	222.01	212.31	663.69	564.30	745.47
	Fees to hospitals and others	135.72	173.57	184.01	432.69	560.49	654.68
	Other expenses	400.99	396.15	385.15	1,189.59	1,197.00	1,574.14
	Total Expenses	1,582.71	1,655.30	1,463.05	4,781.47	4,184.05	5,664.22
3	Profit before tax (1) - (2)	254.78	254.04	160.95	740.84	474.03	700.07
4	Tax expenses						
	Income Tax charge	37.55	50.85	27.60	128.86	82.75	114.42
	Income Tax charge relating to earlier year	0.50	-	(0.15)	0.50	(6.41)	(6.41)
	Deferred tax charge	22.58	7.23	3.76	42.16	16.57	23.69
	Total tax expenses	60.63	58.08	31.21	171.52	92.91	131.70
5	Profit for the period (3) - (4)	194.15	195.96	129.74	569.32	381.12	568.37
6	Other comprehensive income						
	Items that will not be reclassified subsequently to profit and loss						
	Re-measurement gains / (losses) on defined benefit plans	(1.36)	(0.67)	3.55	(2.75)	7.69	(1.78)
	Income tax effect	0.34	0.17	(0.87)	0.69	(1.94)	0.45
	Total other comprehensive income for the period/year	(1.02)	(0.50)	2.68	(2.06)	5.75	(1.33)
7	Total comprehensive income for the period/year, net of tax (5+6)	193.13	195.46	132.42	567.26	386.87	567.04
	Profit for the period/year						
	Attributable to:						
	Equity Holders of the Holding Company	194.15	195.96	129.74	569.32	381.12	568.37
	Non Controlling Interests	-	-	-	-	-	-
		194.15	195.96	129.74	569.32	381.12	568.37
	Total other comprehensive income / (loss) for the period/year attributable to:						
	Equity Holders of the Holding Company	(1.02)	(0.50)	2.68	(2.06)	5.75	(1.33)
	Non Controlling Interests	-	-	-	-	-	-
		(1.02)	(0.50)	2.68	(2.06)	5.75	(1.33)
	Total comprehensive income for the period /year attributable to:						
	Equity Holders of the Holding Company	193.13	195.46	132.42	567.26	386.87	567.04
	Non Controlling Interests	-	-	-	-	-	-
		193.13	195.46	132.42	567.26	386.87	567.04
8	Paid-up equity share capital (Face Value of Rs. 5/- each)	161.45	161.45	161.45	161.45	161.45	161.45
	Other equity						7,936.57
	Earnings per share (Not annualised for quarter & nine months):						
	Basic (Rs.)	6.01	6.07	4.09	17.63	12.10	17.90
	Diluted (Rs.)	5.88	5.92	3.97	17.26	11.71	17.31



For and on behalf of Board of Directors
Krsnaa Diagnostics Limited

Rajendra Mutha
Chairman & Whole-time Director
DIN: 01066737

Krsnaa Diagnostics Limited

CIN:L74900PN2010PLC138068

Notes to Unaudited Consolidated Financial Results:

2. These Consolidated unaudited financial results have been reviewed by the Audit Committee on February 11, 2025 and approved by the Board of Directors at its meeting held on February 12, 2025.

3. The above Statement has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015, as amended.

4. The Group's operations predominantly relate to providing diagnostic services in radiology and pathology services. The Chief Operating Decision Maker (CODM) reviews the operations of the Group as one operating segment. Hence, no separate segment information has been furnished herewith.

5. Pursuant to search and seizure proceedings initiated under the provisions of section 132(1) and section 133A of the Income Tax Act, 1961 on the holding company on July 20, 2022, an assessment order dated March 31, 2024 u/s 143(3) of the Income Tax Act, 1961 ("the Order"), has been received by the holding company for the assessment year ("AY") 2022-23. The Income tax authorities have allegedly made additions on account of undisclosed income and disallowance of certain deductions claimed by the holding company in the tax returns filed in respect of AY 2022-23 and raised a demand of Rs.196.3 million.

The holding company has provided the requisite disclosure to the stock exchange on July 29, 2022, with respect to the search operations, and on April 1, 2024, with respect to the receipt of the Order in accordance with Regulation 30 of the SEBI (LODR) Regulations, 2015 (as amended). The holding company has filed an appeal with the Joint Commissioner (Appeals) or Commissioner of Income-Tax (Appeals) against the Order on April 29, 2024, and have paid tax under protest on August 6, 2024, amounting to Rs. 39.26 million.

The management of the holding company, based on available information, underlying evidence and opinion from tax consultants and experts, is of the view that the said demand is not tenable and will not have any material impact on the holding company's financial position as of December 31, 2024, and on its performance for the quarter and nine months ended on that date.

6. Previous period/year figures have been regrouped/ rearranged wherever considered necessary.



For and on behalf of Board of Directors
Krsnaa Diagnostics Limited

Rajendra Mutha
Chairman & Whole-time Director
DIN: 01066737

Place: Pune

Date: February 12, 2025